The Safety Rates Drug Report

Member Login
2004.Q1    2004.Q2    2004.Q3    2004.Q4    2005.Q1    2005.Q2    2005.Q3    2005.Q4    2006.Q1    2006.Q2    2006.Q3    2006.Q4    2007.Q1    2007.Q2    2007.Q3    2007.Q4    2008.Q1    2008.Q2    2008.Q3    2008.Q4    2009.Q1    2009.Q2    2009.Q3    2009.Q4    2010.Q1    2010.Q2    2010.Q3    2010.Q4    2011.Q1    2011.Q2    2011.Q3    2011.Q4    2012.Q1    2012.Q2    2012.Q3    2012.Q4    2013.Q1    2013.Q2    2013.Q3    2013.Q4    2014.Q1    2014.Q2    2014.Q3    2014.Q4    2015.Q1    2015.Q2    2015.Q3    2015.Q4    2016.Q1    2016.Q2    2016.Q3   

Drug     Injury     Quarter    

Person who experienced the adverse event (patient)

Event ID CASEID CASEVERSION I F COD EVENT DT MFR DT INIT FDA DT FDA DT REPT COD AUTH NUM MFR NUM MFR SNDR LIT REF AGE AGE COD AGE GRP GNDR COD E SUB WT WT COD REPT DT TO MFR OCCP COD REPORTER COUNTRY OCCR COUNTRY
126923972 12692397 2 F 20160824 20160828 20160830 EXP PHHY2016IT115212 SANDOZ MAFFINI E, GIACCONE L, FESTUCCIA M, BRUNELLO L, BUONDONNO I, FERRERO D ET AL. RUXOLITINIB IN STEROID REFRACTORY GRAFT-VS.-HOST DISEASE: A CASE REPORT. JOURNAL OF HEMATOLOGY AND ONCOLOGY. 2016;9(1):ARTICLE NUMBER 67. 51.00 YR M Y 0.00000 20160830 COUNTRY NOT SPECIFIED IT

Drug(s) used by person

Event ID CASEID DRUG SEQ ROLE COD DRUGNAME PROD AI VAL VBM ROUTE DOSE VBM CUM DOSE CHR CUM DOSE UNIT DECHAL RECHAL LOT NUM EXP DT NDA NUM DOSE AMT DOSE UNIT DOSE FORM DOSE FREQ
126923972 12692397 1 PS CICLOSPORIN CYCLOSPORINE 1 Unknown 1.5 MG/KG, BID FROM DAY -1 U 65017 1.5 MG/KG BID
126923972 12692397 2 SS CICLOSPORIN CYCLOSPORINE 1 Oral UNK U 65017
126923972 12692397 3 SS CICLOSPORIN CYCLOSPORINE 1 Unknown (1.5 MG/KG TWICE DAILY, FROM DAY -1) U 65017 1.5 MG/KG BID
126923972 12692397 4 SS RUXOLITINIB RUXOLITINIB 1 Oral 5 MG, BID ON DAY 33 Y 0 5 MG BID
126923972 12692397 5 SS RUXOLITINIB RUXOLITINIB 1 Oral 5 MG, QD ON DAY 100 Y 0 5 MG QD
126923972 12692397 6 SS RUXOLITINIB RUXOLITINIB 1 Oral 5 MG, QD ON DAY 107 Y 0 5 MG
126923972 12692397 7 SS RUXOLITINIB RUXOLITINIB 1 Oral 5 MG, QD ON DAY 113 Y 0 5 MG QD
126923972 12692397 8 SS BUDESONIDE. BUDESONIDE 1 Oral 3 MG, TID ON DAY 28 U 0 3 MG TID
126923972 12692397 9 SS METHOTREXATE. METHOTREXATE 1 Unknown 15 MG/M2, 24 H AFTER TRANSPLANT U 0 15 MG/M**2
126923972 12692397 10 SS METHOTREXATE. METHOTREXATE 1 Unknown 10 MG/M2, ON DAYS 3, 6, AND 11 U 0 10 MG/M**2
126923972 12692397 11 SS MYCOPHENOLATE MOFETIL. MYCOPHENOLATE MOFETIL 1 Intravenous (not otherwise specified) 1 G, TID ON DAY 29 Y 0 1 G TID
126923972 12692397 12 SS THYMOGLOBULIN LAPINE T-LYMPHOCYTE IMMUNE GLOBULIN 1 Unknown 2.5 MG/KG, ON DAYS -3 AND -2 U 0 2.5 MG/KG
126923972 12692397 13 SS THYMOGLOBULIN LAPINE T-LYMPHOCYTE IMMUNE GLOBULIN 1 U 0

Indications of drugs used

Event ID CASEID INDI DRUG SEQ INDI PT
126923972 12692397 1 Stem cell transplant
126923972 12692397 2 Prophylaxis against graft versus host disease
126923972 12692397 4 Acute graft versus host disease in intestine
126923972 12692397 8 Graft versus host disease in gastrointestinal tract
126923972 12692397 9 Stem cell transplant
126923972 12692397 10 Prophylaxis against graft versus host disease
126923972 12692397 11 Graft versus host disease in gastrointestinal tract
126923972 12692397 12 Stem cell transplant
126923972 12692397 13 Prophylaxis against graft versus host disease

Outcome of event

Event ID CASEID OUTC COD
126923972 12692397 HO
126923972 12692397 OT

Reactions reported

Event ID CASEID DRUG REC ACT PT
126923972 12692397 Abdominal pain
126923972 12692397 Acute graft versus host disease in intestine
126923972 12692397 Diarrhoea
126923972 12692397 Drug ineffective
126923972 12692397 General physical health deterioration
126923972 12692397 Pancytopenia
126923972 12692397 Product use issue

Reporting Sources (this data is often not reported and may therefore be missing here)

no results found

Therapies reported

no results found